Lipoprotein(a), what the value really says about your risk

What is lipoprotein(a) anyway?

Lp(a) is an LDL particle with an additional protein attached to it, apolipoprotein(a). It is small enough to penetrate the vessel wall, and it deposits there. That is how the European guideline on dyslipidaemias describes it. Two things make it special. It brings inflammatory components with it, and it resembles a protein that slows clotting in the blood.

This resemblance has consequences. According to the German Lipid-Liga, Lp(a) weakens that brake. What the body needs Lp(a) for at all remains unclear to this day despite decades of research. The Lipid-Liga says that itself.

What is clear, by contrast, is that a single Lp(a) particle does more damage than a single LDL particle. A genetic analysis of the UK Biobank estimated Lp(a) per particle to be about 6.6 times more damaging to vessels than LDL. But far fewer of them are in circulation. At population level Lp(a) therefore contributes less to overall risk than the more common LDL, as the American College of Cardiology points out explicitly. And the factor applies per particle and comes from a model calculation with gene variants, not from an observational study.

Why can I not change my Lp(a) value?

Because it is almost entirely written in your genes. According to the European professional societies, more than 90 percent of the value lies in predisposition, more than for any other blood fat, and the German guideline says the same. Responsible for this is, among other things, a repeat structure in the LPA gene which, according to the same paper, explains 30 to 70 percent of the differences between people on its own.

Your value is therefore not a result of how you live. The gene is fully active from the second year of life, and adult values are usually reached at about five years of age.

After that the value stays largely the same. In a meta-analysis with 6,597 people from seven studies and an average of 8.3 years between measurements, the repeat measurements within one person agreed well. In the American ARIC study, which re-examined 4,734 people after around 15 years, the mean change was 3.1 mg/dl. That is why a single measurement in a lifetime is usually enough.

You should know of one exception. In the same ARIC study, of the people in the grey zone between 30 and 49 mg/dl, 58 percent were above 50 mg/dl at the second measurement. Values below 30 and above 50 mg/dl stayed stable. A result just below the threshold is therefore not very reliable.

Since 2025 there has also been debate about whether a single measurement really suffices. A study of 1,263 patients found a change of at least 20 percent between two measurements in around 44 percent of them. That has not changed the guideline recommendation so far, but the question is open.

Why must I not convert mg/dl into nmol/l?

Because the two units measure different things. nmol/l counts how many Lp(a) particles are in circulation in the blood. mg/dl describes how heavy they are together. Because individual particles vary in size and weight, every conversion remains an approximation. The European professional societies therefore explicitly advise against using a fixed conversion factor.

As a rough rule of thumb, a factor of 2 to 2.5 is sometimes used. The professional societies themselves write that this is at best an estimate, and in their follow-up paper of 2023 they state that it is not scientifically correct.

How uncertain this is, the guidelines demonstrate on themselves. In 2022 the European consensus statement equated 50 mg/dl with 125 nmol/l; in 2025 the same body equated the same 50 mg/dl with 105 nmol/l. Same threshold, same authors, a different number three years later.

On top of that, test methods are not yet uniformly calibrated worldwide. Depending on the laboratory, the same sample can come out somewhat higher or lower. Close to a threshold, that decides the matter. Since 2026 there is at least an internationally agreed reference method.

Two things follow for you. Assess your value in the unit in which it was measured, and go to the same laboratory for any repeat measurement.

How do I place my value in context?

There are three ranges with fluid transitions. Below 30 mg/dl a risk from Lp(a) counts as unlikely. Above 50 mg/dl the value counts as a risk factor for heart and vessels according to the guideline. In between lies a grey zone. Which nmol/l values belong to it is shown in the table below.

More important than the classification is one sentence from the European consensus statement. The risk rises evenly with the level of the value, without a jump at a threshold. Anyone who breathes out at 48 mg/dl and falls into worry at 52 mg/dl is reading two numbers that mean practically the same thing.

In risk calculation a raised value nevertheless has an effect. In the update of 2025 the European professional societies name raised Lp(a) as one factor that can justify classification in the next higher risk category. The step up by one category is not prescribed; it is explicitly possible.

A model calculation based on the British UK Biobank gives an order of magnitude. Compared with an Lp(a) of 7 mg/dl, the population mean, the lifetime risk of heart attack, stroke and related conditions at 30, 50, 75, 100 and 150 mg/dl was estimated to be higher by a factor of 1.22, 1.40, 1.65, 1.95 and 2.72. These are model calculations from a large database, not a prediction for an individual person.

One point is missing from almost all German texts. The distribution of values depends on ancestry. The European consensus statement gives mean values of 16, 19, 31 and 75 nmol/l in Chinese, White, South Asian and Black people. The effect per step is the same everywhere; what differs are the starting values.

Is the fuss about Lp(a) overdone?

The question is legitimate, because in Germany the professional societies are arguing about exactly this. General practitioners advise against determining the value routinely; cardiologists openly disagree. Both sides have an argument you should know, and both put it more cautiously than the excitement online suggests.

The de-dramatising comes from research itself. Florian Kronenberg, first author of the European consensus statement, told Austrian broadcaster ORF that the most important thing is not to panic. Without further risk factors such as high blood pressure or diabetes, a raised value carries less weight on that view.

DEGAM, the professional society of general practitioners, advises in its guideline of November 2024 against determining Lp(a) routinely in addition to the classic risk factors. Directly below that stands the note that six other professional societies, among them the German Cardiac Society, do not agree.

The general practitioners' argument is not that the association does not exist. What is disputed is the added value. In an analysis of 24 studies with 133,502 participants, the discriminatory power of the prediction rose by only 0.0016 when Lp(a) was added. Studies demonstrating a benefit of systematic measurement are lacking. Taking an already available value into account is, however, explicitly permitted by the same guideline.

The cardiologists push back. At least one person in five is affected, and the risk remains even when LDL cholesterol is well controlled. An analysis of 27,658 people from six statin trials showed in 2025 that an Lp(a) above 50 mg/dl raises the risk across all ranges of achieved LDL cholesterol, including the lowest quartile.

Formally both sides remain cautious. The European guideline says a one-off measurement should be considered, not that it must happen. What is new is that the US guideline of March 2026 strongly recommends it for all adults for the first time, and additionally advises measuring in parents, siblings and children of those affected.

Our position is unspectacular. The association is well established; the number remains information and not a diagnosis.

What can you influence and what not?

The Lp(a) value itself, barely. The European consensus statement gives no to minimal influence for exercise and none at all for fasting. A low-carbohydrate, high-fat diet lowered the value in studies by 10 to 15 percent, which changes nothing about the classification. What stays movable is the rest of your risk profile, meaning blood pressure, LDL cholesterol, smoking, blood sugar and weight.

Statins do not lower Lp(a) specifically either. In an analysis of seven studies with 14,536 patients, pooled, minus 0.4 percent remained, with a range from minus 7 to plus 7 percent, so no established effect. Other studies even found a slight rise of around 11 percent; the European professional society calls the picture confusing itself. You should nevertheless not stop statins at high Lp(a), because they act via LDL cholesterol.

Other lipid-lowering drugs change Lp(a) measurably without being approved for it. PCSK9 inhibitors and inclisiran lowered the value by a pooled around 26 percent in an analysis of 31 randomised trials, and the agent obicetrapib by about 37 percent according to an analysis of 2,356 high-risk patients. For none of them is it established that lowering Lp(a) itself reduces risk. They are used because of LDL cholesterol.

Lifestyle is nevertheless not irrelevant; it simply acts elsewhere. In the British EPIC-Norfolk study, 14,051 people were followed for an average of 11.5 years, during which 1,732 cardiovascular events occurred. Among those with an Lp(a) above 50 mg/dl, the group with the most favourable health profile had around two thirds fewer events than the least favourable.

Two qualifications belong with that. The profile comprised seven characteristics and included values controlled with medication, such as blood pressure and cholesterol, so it is not about lifestyle alone. And it is an observed association in which other influences cannot be ruled out, not a promise for you personally.

Is there a treatment for high Lp(a)?

A medicine that specifically lowers Lp(a) is not yet approved. As of 10 August 2026 there is only one procedure that directly lowers raised Lp(a) and is covered by statutory health insurance: lipoprotein apheresis. That is a form of blood cleansing and not a medicine, recognised by the Gemeinsamer Bundesausschuss as a last resort in courses that cannot otherwise be controlled.

The requirements are narrow. What is demanded is an isolated raised Lp(a) above 60 mg/dl, an LDL cholesterol in the normal range and a progressive vascular disease documented clinically and on imaging. A commission at the regional association of statutory health insurance physicians advises on the individual case, the health insurer has to approve it, and the approval is valid for one year.

According to the directive, at least 60 percent of Lp(a) is removed per session, after which the value rises again. Averaged over the interval, a reduction of about 30 to 35 percent remains with weekly treatment, according to the specialist literature.

New agents lower Lp(a) considerably in studies, by 70 to over 90 percent at the highest doses. What is decisive is the gap behind that. For none of them have data on heart attacks, strokes or deaths been published so far. Five large outcome trials are running; the most advanced has announced its results for the second half of 2026, the others run until 2028 and beyond.

There has been an intermediate step since 2026. In a study of 51 German patients who had to attend apheresis regularly, the agent pelacarsen almost completely removed the need for apheresis over one year, with an Lp(a) reduction of around 72 percent. That is a meaningful endpoint, but not proof that heart attacks or strokes are thereby prevented.

The European professional society writes itself that it has not yet been shown that lowering Lp(a) reduces the risk of cardiovascular disease. Where Lp(a) is raised, the guidelines therefore advise treating the remaining risk factors consistently.

Who pays for the measurement in Germany?

The statutory check-up does not cover Lp(a). It contains four blood fat values, namely total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. Between 18 and 35 this blood panel is only available at all where there is a corresponding risk profile, for instance heart attacks in the family, marked excess weight or high blood pressure. From 35 it belongs to it without precondition.

As an individual service the billing item nevertheless exists. In the catalogue of the statutory insurers Lp(a) is valued at €10.95, without restriction to particular conditions. Where a medical indication exists, the test is covered by statutory insurance. Your doctor decides that.

Why the request in a general practice is nevertheless often refused has a factual reason. Practices receive a bonus for ordering laboratory services economically. This bonus tapers off as soon as the laboratory costs ordered exceed a certain value in the quarterly average across all treatment cases. In general medicine the lower limit is €1.42 and the upper €3.37. It is therefore not your single measurement that is the problem, but the sum across many patients. The laboratory is paid for the service in every case.

As a self-payer the laboratory service alone costs €17.49 at the single rate and €20.11 at the 1.15-fold rate, which is the upper limit for laboratory services. Blood collection and the fee are added to that. Transparency note: NOA Health offers the measurements described here itself.

What does the value mean if you are in your early 30s?

It is a planning figure and not an alarm signal. The European risk calculators SCORE2 and SCORE2-OP start at 40 years, so for a healthy 30-year-old this calculation does not exist at all. That also removes the step up because of a raised Lp(a); there is no category from which you could move up. What makes sense instead is to look at lifetime risk rather than at the next ten years. A raised value does not mean that something is about to happen, but that an unchangeable factor runs alongside for decades.

How little there is to decide in the short term is shown by the research. The first large study on the question of whether lowering Lp(a) achieves anything in people without a previous event began in 2025 and runs until 2031.

Your number does not change what to do today. It changes how consistently you do it. Taken on its own it carries no conclusion; placing it in context belongs in a medical assessment together with family history, blood pressure and blood fats.